SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 22nd, 2019 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 22nd, 2019 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of January 18, 2019, between Can-Fite BioPharma Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CAN-FITE BIOPHARMA LTD.Warrant Agreement • January 22nd, 2019 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations
Contract Type FiledJanuary 22nd, 2019 Company IndustryTHIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after January [__], 2019 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ____________________1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Can-Fite BioPharma Ltd., an Israeli limited company (the “Company”), up to ______ Ordinary Shares (the “Warrant Shares”) represented by ________2 American Depositary Shares (“ADSs”), as subject to adjustment hereunder (the “Warrant ADSs”). The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b).